SHED-Exo ameliorate age-related OP by activating mitophagy in senescent BMSCs, serving as a novel translational nanotherapeutic for age-related bone disorders.
Yang et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: